French startup Sonio has raised €5 million in funding to develop an AI software that empowers fetal medicine professionals to secure pregnancy care.
The round was led by Elaia, alongside OneRagtime and Bpifrance. The funding will allow Sonio to accelerate its entry in the U.S. and get FDA clearance, ramp up sales in Europe and add embedded image recognition into its platform.
Founded in 2020, Sonio aims to improve access and quality of care for pregnant women and children. The company has brought together expertise from fetal medicine, AI, software development and imaging to address 50% of congenital malformations that are not detected before birth with a comprehensive solution to assist all fetal ultrasound practitioners. It is currently being used by 150 healthcare professionals in Europe.
Cécile Brosset, CEO and co-founder said: “Sonio addresses important issues for both pregnant women and fetal medicine practitioners with a unique combination of AI and clinical expertise. This new round of financing will allow us to recruit the talents we need both in software development and sales, and bring to the market our full suite of products.”
The startup has already inked partnerships with Samsung France, one of the main ultrasound manufacturers and private clinics like PointGyn (OneClinic) in France and GynEcho in Canada.
Benoît Georis, investment director at Elaia added: “We have found all key ingredients for success in Sonio. A seasoned and market savvy team of founders, a solid and patented deep technology platform, and a market ready for take off.”
“After supporting Sonio with convertible bonds under the French Tech Seed Fund, Bpifrance is proud to support its commercial acceleration and its technological innovations. We were seduced by the unique user experience offered by the platform and its ability to secure practice by creating value for all medical staff and patients.” Eva Clerc, investment director at Bpifrance added.